
Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)
The Chinese National Medical Products Administration (NMPA) has approved Nubeqa™ (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at […]